HC Wainwright Reiterates Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $20.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 103.87% from the company’s current price. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ FY2029 earnings at $1.24 EPS.

KALV has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock opened at $9.81 on Friday. The business has a 50 day simple moving average of $10.90 and a 200-day simple moving average of $11.82. KalVista Pharmaceuticals has a 12 month low of $7.39 and a 12 month high of $16.88. The stock has a market capitalization of $423.99 million, a PE ratio of -2.70 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.04. As a group, equities research analysts anticipate that KalVista Pharmaceuticals will post -2.7 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,400 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,016 shares of company stock valued at $319,344 in the last ninety days. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC raised its position in shares of KalVista Pharmaceuticals by 0.5% in the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock valued at $48,775,000 after buying an additional 20,000 shares during the last quarter. Vestal Point Capital LP grew its stake in KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after acquiring an additional 1,700,000 shares during the period. Great Point Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the 2nd quarter worth $15,768,000. State Street Corp lifted its stake in shares of KalVista Pharmaceuticals by 68.1% during the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after purchasing an additional 515,179 shares during the period. Finally, Emerald Advisers LLC lifted its stake in shares of KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).